Emanuel Stutz
Overview
Explore the profile of Emanuel Stutz including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
154
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Berclaz L, Jurinovic V, Burkhard-Meier A, Abdel-Rahman S, Albertsmeier M, Klein A, et al.
Cancer Med
. 2025 Feb;
14(4):e70655.
PMID: 40007213
Background: Dacarbazine is currently considered the better combination partner for doxorubicin compared to ifosfamide for the treatment of leiomyosarcoma (LMS). Regional hyperthermia (RHT) combined with neoadjuvant chemotherapy has been shown...
2.
Bachmann N, Schmidhalter D, Corminboeuf F, Berger M, Borbely Y, Ermis E, et al.
Adv Radiat Oncol
. 2024 Dec;
10(1):101656.
PMID: 39628955
Purpose: Radiation therapy (RT) plays a key role in the management of esophageal cancer (EC). However, toxicities caused by proximity of organs at risk (OAR) and daily target coverage caused...
3.
Roohani S, Ehret F, Beck M, Veltsista D, Nadobny J, Zschaeck S, et al.
Int J Hyperthermia
. 2024 Apr;
41(1):2342348.
PMID: 38653548
Purpose: To analyze the current practice of regional hyperthermia (RHT) for soft tissue sarcoma (STS) at 12 European centers to provide an overview, find consensuses and identify controversies necessary for...
4.
Riesterer O, Ademaj A, Puric E, Eberle B, Beck M, Gomez S, et al.
Int J Hyperthermia
. 2022 Aug;
39(1):1078-1087.
PMID: 35993234
Background: Transurethral resection of bladder tumor (TUR-BT) followed by chemoradiation (CRT) is a valid treatment option for patients with muscle-invasive bladder cancer (MIBC). This study aimed to investigate the efficacy...
5.
Stutz E, Puric E, Ademaj A, Kunzi A, Krcek R, Timm O, et al.
Cancers (Basel)
. 2022 Mar;
14(5).
PMID: 35267486
Background: Moderate hyperthermia is a potent and evidence-based radiosensitizer. Several indications are reimbursed for the combination of deep hyperthermia with radiotherapy (dHT+RT). We evaluated the current practice of dHT+RT in...
6.
Notter M, Stutz E, Thomsen A, Kollar A, Vaupel P
Cancers (Basel)
. 2021 Nov;
13(22).
PMID: 34830861
On 2 July 2021, Kronenfeld et al. [...].
7.
Issels R, Noessner E, Lindner L, Schmidt M, Albertsmeier M, Blay J, et al.
Eur J Cancer
. 2021 Oct;
158:123-132.
PMID: 34666214
Background: The EORTC 62961-ESHO 95 randomised trial showed improved long-term survival of patients with high-risk soft-tissue sarcoma by adding regional hyperthermia to neoadjuvant chemotherapy. We hypothesised that immune infiltrate of...
8.
Notter M, Stutz E, Thomsen A, Vaupel P
Cancers (Basel)
. 2021 Aug;
13(15).
PMID: 34359812
Background: Radiation-associated angiosarcoma of the breast (RAASB) is a rare, challenging disease, with surgery being the accepted basic therapeutic approach. In contrast, the role of adjuvant and systemic therapies is...
9.
Datta N, Marder D, Datta S, Meister A, Puric E, Stutz E, et al.
Int J Hyperthermia
. 2021 Feb;
38(1):296-307.
PMID: 33627018
Background: Thermal dose in clinical hyperthermia reported as cumulative equivalent minutes (CEM) at 43 °C (CEM43) and its variants are based on direct thermal cytotoxicity assuming Arrhenius 'break' at 43 ...
10.
Datta N, Stutz E, Gomez S, Bodis S
Int J Radiat Oncol Biol Phys
. 2021 Jan;
109(2):642-644.
PMID: 33422281
No abstract available.